Webb R L, Navarrete A E, Davis S
Metabolic and Cardiovascular Diseases, Pharmaceuticals Division, Novartis Corp., Summit, New Jersey 07901-1398, USA.
Am J Hypertens. 1998 Jan;11(1 Pt 1):59-65. doi: 10.1016/s0895-7061(97)00309-9.
The purpose of this study was to examine the effectiveness of combined administration of the angiotensin AT1 receptor antagonist valsartan, with the diuretic hydrochlorothiazide (HCTZ), on blood pressure in conscious spontaneously hypertensive rats (SHR). Both drugs were administered continuously via subcutaneously implanted osmotic minipumps alone or in combination for a period of 2 weeks. Mean arterial pressure and heart rate were monitored throughout the infusion interval by means of chronically-implanted radiotransmitters. Coadministration of a diuretic with valsartan potentiated the blood pressure lowering effect in conscious SHR. Responses varied in magnitude from additive (valsartan at 1 mg/kg/day + hydrochlorothiazide at 3 and 10 mg/kg/day) to synergistic (valsartan at 3 mg/kg/day + hydrochlorothiazide at 10 mg/kg/day). The greater blood pressure lowering seen in SHR receiving combination therapy was associated with only a transient increase in heart rate. A similar potentiation of the antihypertensive effect was seen during coadministration of hydrochlorothiazide (HCTZ) with the angiotensin converting enzyme inhibitor benazeprilat. Additivity was noted with benazeprilat at 1 mg/kg/day + hydrochlorothiazide at 3 mg/kg/day, whereas a higher dose of HCTZ resulted in a synergistic response. These findings suggest that the similar results obtained with angiotensin converting enzyme inhibitors and AT1 receptor antagonists are due to the capacity to which diuretic-induced activation of the renin angiotensin system occurs.
本研究的目的是考察血管紧张素AT1受体拮抗剂缬沙坦与利尿剂氢氯噻嗪(HCTZ)联合给药对清醒自发性高血压大鼠(SHR)血压的影响。两种药物单独或联合通过皮下植入的渗透微型泵持续给药2周。在整个输注期间,通过长期植入的无线电发射器监测平均动脉压和心率。在清醒的SHR中,缬沙坦与利尿剂联合给药可增强降压效果。反应程度从相加(缬沙坦1mg/kg/天+氢氯噻嗪3mg/kg/天和10mg/kg/天)到协同(缬沙坦3mg/kg/天+氢氯噻嗪10mg/kg/天)不等。接受联合治疗的SHR中更大程度的血压降低仅与心率短暂增加有关。在氢氯噻嗪(HCTZ)与血管紧张素转换酶抑制剂贝那普利拉联合给药期间也观察到类似的降压作用增强。贝那普利拉1mg/kg/天+氢氯噻嗪3mg/kg/天表现为相加作用,而更高剂量的HCTZ则导致协同反应。这些发现表明,血管紧张素转换酶抑制剂和AT1受体拮抗剂获得的相似结果是由于利尿剂诱导的肾素血管紧张素系统激活的能力。